The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1723
March 3, 2025
View Complete Issue         Table of Contents 2019 
A Renal Indication for Semaglutide (Ozempic)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Renal Indication for Semaglutide (Ozempic)
March 3, 2025 (Issue: 1723)
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Renal Indication for Semaglutide (Ozempic)
Article code: 1723d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.